Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of TGF-beta1 inhibitory polypeptide on immune response modifier preparation

A technology of immune response and modulators, applied in the direction of allergic diseases, peptide/protein components, and diseases transmitted by vectors, and can solve problems that do not involve the use of immunomodulators

Inactive Publication Date: 2009-01-07
PROYECTO DE BIOMEDICINA CIMA
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This document protects the disclosed peptide p17 (SEQ ID NO: 2) and its use, but it still does not refer to its use in the preparation of immunomodulators

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of TGF-beta1 inhibitory polypeptide on immune response modifier preparation
  • Application of TGF-beta1 inhibitory polypeptide on immune response modifier preparation
  • Application of TGF-beta1 inhibitory polypeptide on immune response modifier preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] This example investigates the effect of the peptide p144 in a system in which exogenous TGF-β1 is used as an inducer of the differentiation of splenocyte populations into dendritic cells.

[0060] Isolation and culture of dendritic cells

[0061] After sacrifice of 8-week-old male C57 mice, their spleens were aseptically extracted and homogenized on plates with clean medium to generate cell suspensions. Centrifuge the cells at 1000 rpm for 5 minutes, and use 1 ml / spleen of ACK lysis solution (0.15M NH 4 Cl, 1 mM KHCO 3 , 0.1M EDTA sodium salt solution, pH 7.2-7.4) and resuspend the resulting cell pellet at 37°C for 1 min. Next, centrifuge the cells and use 10 ml of cold R10 medium (RPMI-1640, 10% FBS, glutamine, 2×10 -5 M 2-mercaptoethanol) to wash the cells to centrifuge and wash again. Finally, the cells were resuspended in 50 ml of R10 medium. Prepare a 6-well plate (Costar#3471), and use 1ml of R10 per well to treat them for 15 minutes at room temperature to d...

Embodiment 2

[0072] In vivo activity of recombinant adenovirus for mouse IL-12

[0073] This example investigates the role of the peptide p144 in an in vivo system in which TGF-β1 acts as a putative antagonist of the cytokine induced in this model. Mouse IL-12 produced by expression of the transgene contained within the recombinant adenovirus induces an inflammatory state through the induction of a cascade of factors including IFN-γ and nitric oxide. TGF-β1 has been described as an inhibitor of the production and biological effects of IL-12, IFN-γ and NO (Pardoux C. et al., 1999; Schini V.B. et al., 1992). In this model, groups of 3 BALB / c mice were intraperitoneally administered 1×10 8 pfu of mouse RAd IL-12, the mice were 4 to 8 weeks old (Harlan), and the animals were allocated as follows:

[0074] Rad IL-12: The animals received 1 x 10 8 pfu of mouse RAd IL-12.

[0075] Rad IL-12+p144: the animals received the same treatment as the previous group, but they were given the peptide fo...

Embodiment 3

[0094] antibody induction

[0095] For the analysis of the immunomodulatory effect of peptide pl44 on humoral responses, 6- to 8-week-old female BALB / c mice (Harlan, Barcelona) were used. For the induction of specific antibodies, inactivated recombinant adenovirus (RAd-LacZ) was inoculated by heating in a water bath at 100° C. for 10 minutes.

[0096] Animal groups and treatments

[0097] Three mice per group were immunized with 200 μl of intraperitoneal mixture containing 1 × 10 8 pfu of inactivated RAd-LacZ adenovirus, physiological serum (PS) or peptide p144 with 50 μg, all as indicated in Table M4, emulsified in Freund's complete adjuvant (FCA) in a 1:1 volume ratio. Thirty days after the first immunization, the animals were immunized again with the same mixture but emulsified in Freund's incomplete adjuvant (FIA). Blood samples were taken from the retroorbital plexus on days 15 and 45 to quantify the production of anti-adenovirus antibodies by each animal.

[0098] To...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Volumeaaaaaaaaaa
Login to View More

Abstract

The invention relates to a TGF-ss1 inhibitor peptide which is selected from among: peptide p144 having a sequence that corresponds to SEQ ID NO: 1, peptide p17 having a sequence that corresponds to SEQ ID NO: 2, a peptide that has at least 90 % homology with said peptides, or fragments of same. The invention relates to the use of said peptide in the preparation of an immune response modulating agent.

Description

field of invention [0001] The invention belongs to the field of preparation of immune response regulators. Background of the invention [0002] TGF-β1 (transforming growth factor β1) is a powerful immune regulator, which exists in various stages of immune response and produces different effects. It is now known to be a potent regulator of immune system cells including lymphocytes, macrophages and dendritic cells (Letterio J.J., 1998). [0003] The biological activity of TGF-β1 varies widely depending on the type and state of cell differentiation, as well as the presence of other cytokines, suggesting that changes in the balance of this group of cytokines can also affect TGF-β1 and contribute to the interaction with the immune system. Development of dysfunction-related pathology. TGF-β1 modulates the immune response in a complex, context-dependent manner, revealed by using experimental models of different diseases for the evaluation of genetically modified mice with respect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/18A61K38/08A61K38/10A61P37/02
CPCA61K38/10A61P35/00A61P37/02Y02A50/30
Inventor 弗朗西斯科·博拉斯奎斯塔诺利埃·卡撒瑞斯阿加哈维尔·多托尔德拉斯埃雷里亚斯露西娅·吉尔格雷罗胡安·何塞·拉萨尔特萨加斯蒂韦尔萨帕布鲁·萨罗韦乌加里萨赫苏斯·普列托巴尔图埃纳
Owner PROYECTO DE BIOMEDICINA CIMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com